Ruti Aga's Six Years: Methylprednisolone Is Not a Steroid, and That Is the Real Story

Six years. Two for presence, four for tampering. When an anti-doping decision arrives with arithmetic that clean, my habit is to check the sum before reading the story. Ruti Aga's case survives that check. The report that carried the sum, though, attached a word that appears nowhere on the World Anti-Doping Agency's Prohibited List: methylprednisolone, described as a prohibited steroid classed as performance-enhancing by WADA. Both claims are wrong. The tape disagreed with the table, so I kept watching — and what surfaced is a story about paperwork.

Context

Aga is 32, Ethiopian, the 2026 Tokyo Marathon champion, with three second-place finishes at World Marathon Majors. In March she won a half marathon in China; the source gives no time, no splits, no field strength. Her in-competition sample from that race returned methylprednisolone. [Source: Athletics Integrity Unit statement, Thursday]

The defence: a knee injury, treated by injection. The doctor who wrote the prescription was a family member with no medical registration. The clinic named on the paper did not exist. Questioned, the explanation ran that an old prescription pad from a former workplace had been lying around — and the clinic disowned it outright. Three separate verifications, three failures. Provisional suspension ran from 10 September; the ban is six years.

Core: route and timing were the whole case

On WADA's list methylprednisolone is a glucocorticoid, class S9, not an anabolic steroid. S9 is prohibited in-competition only, and only by injection, oral or rectal route. A road race's testing window opens at 23:59 the night before, which means an injection given days earlier still lands inside it.

Intra-articular methylprednisolone for knee synovitis is ordinary sports medicine in distance runners, as routine as icing is for a fast bowler. That plausibility is why the defence reads seriously at first pass. It is also why the forgery decides everything. A genuine treatment gets defended with genuine records: a real prescription, a real clinic, a real registration number, and a documented line from injection to start line. None of the four existed.

The deficit sits in the entourage, not the syringe. In 2026, recording The Fourth Place podcast from a rented spare room in Hackney, I built a 62-thrower javelin spreadsheet and put a source line under every number. That habit earns its keep here. Aga had no credentialed team physician, no TUE infrastructure, and nobody holding a washout calendar. Podium-funding systems in the UK bind medical staff to the athlete alongside the lottery money; Railways and Services jobs in India deliver security and regional employment, and they carry paperwork of their own kind. In East African road racing that paperwork tends to fall between the agent and the appearance fee: the money sits at the start line, not in the medical file.

China's label-race circuit now sits exactly where the appearance-fee economy and the AIU's testing economy collide — big fees, deep East African fields, and the highest-yield testing ground on the road calendar, all inside the same race.

What survives is the 2026 Tokyo title. The violation is anchored to the March race, so earlier results are not automatically annulled. The source does not state the disqualification scope, and in 2026, calling 22 matches from an isolation booth in Salford, I learned that silence is a material. This silence is the loudest thing in the file. What is visible: age 32, six years, a return at roughly 38. Ethiopian women's marathon depth does not hand a 2:18 athlete a team place on sentiment. Track taught me the clock; the arena taught me the noise — and the clock says the selection door stays shut even after the ban expires.

Contrarian: the boring consensus is right, and I am logging it

The easy counter-take is that the AIU goes harder at African road runners. I tested it. Two years for presence is the standard Specified Substance outcome; the extra four came from her own conduct, not her passport. Forgery is a documentary fact, not an inference. The dull consensus — that she earned the six — holds. I am putting that on the record because the ENTP reflex hunts for the inverted read, and here the inverted read collapses. Follow the pattern until it contradicts itself; this one contradicts the contrarians first.

One media error does real damage, though: calling it a steroid. That reframes a timing-and-route case as a doping-morality case and invites comparison with anabolic files where the sentencing logic runs differently. A glucocorticoid does not build endurance; it suppresses pain, which makes running hurt possible. That carries its own risk without borrowing a scarier vocabulary. The numbers were never the point — the argument they started was.

Takeaway

The next anti-doping fight is over paper, not needles: prescriptions, TUE files, clinic stamps, and the timelines nobody keeps. The question is not when the next case lands. It is who audits the entourage that produced this prescription — and how long nobody does.